Search

ACADIA Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

29.61 0.78

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

28.97

Макс.

29.62

Ключевые показатели

By Trading Economics

Доход

-270M

3.6M

Продажи

-16M

268M

P/E

Средняя по отрасли

11.588

68.51

Прибыль на акцию

0.02

Рентабельность продаж

1.357

Сотрудники

796

EBITDA

-19M

7M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+16.64% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

586M

4.4B

Предыдущая цена открытия

28.83

Предыдущая цена закрытия

29.61

Новостные настроения

By Acuity

9%

91%

9 / 340 Рейтинг в Healthcare

ACADIA Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 20:06 UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

6 авг. 2026 г., 23:41 UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

5 авг. 2026 г., 20:02 UTC

News

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

4 авг. 2026 г., 23:01 UTC

News

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

3 авг. 2026 г., 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

31 июл. 2026 г., 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

30 июл. 2026 г., 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

29 июл. 2026 г., 20:41 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading amid a broader market decline linked to rising crude oil prices and geopolitical tensions.

28 июл. 2026 г., 20:06 UTC

ACADIA Pharmaceuticals is rising amid strong performance in the Biotechnology sector. The stock is nearing the upper end of its one-month range.

27 июл. 2026 г., 20:01 UTC

ACADIA Pharmaceuticals Inc. shares are higher today, continuing an upward trend since Friday's close, despite no specific news driving the price movement.

24 июл. 2026 г., 19:56 UTC

ACADIA Pharmaceuticals shares are higher since Thursday's close, despite a dip earlier in the session. The stock remains below its 20-day moving average.

23 июл. 2026 г., 10:06 UTC

ACADIA Pharmaceuticals is trading higher in pre-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

22 июл. 2026 г., 22:16 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading, with unusual activity noted. Broader market concerns may be influencing investor sentiment.

21 июл. 2026 г., 23:16 UTC

ACADIA Pharmaceuticals Inc. shares traded roughly flat in after-market hours, remaining near the upper end of their one-month trading range.

20 июл. 2026 г., 19:56 UTC

Event
News
Social Media

Acadia Pharmaceuticals received Fast Track designation for remlifanserin, but shares are lower today, continuing a trend of declines over the past three sessions.

Сравнение c конкурентами

Изменение цены

ACADIA Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

16.64% рост

Прогноз на 12 месяцев

Средняя 34.07 USD  16.64%

Максимум 39 USD

Минимум 25 USD

Основано на мнении 15 аналитиков Wall Street, спрогнозировавших целевые цены для ACADIA Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

15 ratings

11

Покупка

4

Удержание

0

Продажа

Настроения

By Acuity

9 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat